Flutamide in the treatment of metastatic carcinoma of the prostate.
Twenty-five patients with metastatic carcinoma of the prostate were treated with Flutamide, a non-steroidal anti-androgen. All patients showed progression; the longest response was 120 weeks. The side effects were nausea, vomiting, breast tenderness and gynaecomastia.
D000368:Aged; D000813:Anilides / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000188:drug therapy / Q000556:secondary*; D005485:Flutamide / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000473:pathology*
D000813:Anilides; D005485:Flutamide